<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5630738</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.1113</article-id><article-id pub-id-type="publisher-id">ofx163.1113</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Frame me if you must: PrEP framing and the impact on adherence to HIV Pre-exposure Prophylaxis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ellorin</surname><given-names>Eric</given-names></name><degrees>MAS</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Blumenthal</surname><given-names>Jill</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Jain</surname><given-names>Sonia</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Xiaoying</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Corado</surname><given-names>Katya</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Dube</surname><given-names>Michael</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Moore</surname><given-names>David</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Morris</surname><given-names>Sheldon</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><collab>the California Collaborative Treatment Group</collab><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Medicine, University of California</institution>, <addr-line>San Diego, San Diego, California</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>Family and Preventive Medicine, University of California</institution>, <addr-line>San Diego, La Jolla, California</addr-line></aff><aff id="AF0003">
<label>3</label>
<institution>Los Angeles Biomedical Research Institute at Harbor-UCLA</institution>, <addr-line>Torrance, California</addr-line></aff><aff id="AF0004">
<label>4</label>
<institution>Medicine, University of Southern California</institution>, <addr-line>Los Angeles, California</addr-line></aff><aff id="AF0005">
<label>5</label>
<institution>Psychiatry, UCSD</institution>, <addr-line>San Diego, California</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 158. HIV: Pre-Exposure Prophylaxis</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S439</fpage><lpage>S439</lpage><permissions><copyright-statement>© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.1113.pdf"></self-uri><abstract><title><offsets xml_i="5096" xml_f="5104" txt_i="11" txt_f="19">Abstract</offsets></title><sec id="s1"><title><offsets xml_i="5132" xml_f="5142" txt_i="20" txt_f="30">Background</offsets></title><p><offsets xml_i="5153" xml_f="5456" txt_i="31" txt_f="334">“PrEP whore” has been used both as a pejorative by PrEP opponents in the gay community and, reactively, by PrEP advocates as a method to reclaim the label from stigmatization and “slut-shaming.” The actual prevalence and impact of such PrEP-directed stigma on adherence have been insufficiently studied.</offsets></p></sec><sec id="s2"><title><offsets xml_i="5486" xml_f="5493" txt_i="336" txt_f="343">Methods</offsets></title><p><offsets xml_i="5504" xml_f="6077" txt_i="344" txt_f="917">CCTG 595 was a randomized controlled PrEP demonstration project in 398 HIV-uninfected MSM and transwomen. Intracellular tenofovir-diphosphate (TFV-DP) levels at weeks 12 and 48 were used as a continuous measure of adherence. At study visits, participants were asked to describe how they perceived others’ reactions to them being on PrEP. These perceptions were categorized a priori as either “positively framed,” “negatively framed,” or both. We used Wilcoxon rank-sum to determine the association between positive and negative framing and TFV-DP levels at weeks 12 and 48.</offsets></p></sec><sec id="s3"><title><offsets xml_i="6107" xml_f="6114" txt_i="919" txt_f="926">Results</offsets></title><p><offsets xml_i="6125" xml_f="6597" txt_i="927" txt_f="1399">By week 4, 29% of participants reported perceiving positive reactions from members of their social groups, 5% negative, and 6% both. Reporting decreased over 48 weeks, but positive reactions were consistently reported more than negative. At week 12, no differences in mean TFV-DP levels were observed in participants with positively-framed reactions compared with those reporting no outcome or only negatively-framed (1338 [IQR, 1036-1609] vs. 1281 [946-1489] fmol/punch, </offsets><italic><offsets xml_i="6605" xml_f="6608" txt_i="1399" txt_f="1402">P =</offsets></italic><offsets xml_i="6617" xml_f="6757" txt_i="1402" txt_f="1542"> 0.17). Additionally, no differences were observed in those with negative reactions vs. those without (1209 [977–1427] vs. 1303 [964–1545], </offsets><italic><offsets xml_i="6765" xml_f="6768" txt_i="1542" txt_f="1545">P =</offsets></italic><offsets xml_i="6777" xml_f="6943" txt_i="1545" txt_f="1711"> 0.58). At week 48, mean TFV-DP levels trended toward being higher among those that report any reaction, regardless if positive (1335 [909–1665] vs. 1179 [841–1455], </offsets><italic><offsets xml_i="6951" xml_f="6954" txt_i="1711" txt_f="1714">P =</offsets></italic><offsets xml_i="6963" xml_f="7021" txt_i="1714" txt_f="1772"> 0.09) or negative (1377 [1054–1603] vs. 1192 [838–1486], </offsets><italic><offsets xml_i="7029" xml_f="7032" txt_i="1772" txt_f="1775">P =</offsets></italic><offsets xml_i="7041" xml_f="7250" txt_i="1775" txt_f="1984"> 0.10) than those reporting no reaction. At week 48, 46% of participants reported experiencing some form of PrEP-directed judgment, 23% reported being called “PrEP whore,” and 21% avoiding disclosing PrEP use.</offsets></p></sec><sec id="s4"><title><offsets xml_i="7280" xml_f="7290" txt_i="1986" txt_f="1996">Conclusion</offsets></title><p><offsets xml_i="7301" xml_f="7631" txt_i="1997" txt_f="2327">Over 48 weeks, nearly half of participants reported some form of judgment or stigmatization as a consequence of PrEP use. However, individuals more frequently perceived positively framed reactions to being on PrEP than negative. Importantly, long-term PrEP adherence does not appear to suffer as a result of negative PrEP framing.</offsets></p></sec><sec id="s5"><title><offsets xml_i="7661" xml_f="7672" txt_i="2329" txt_f="2340">Disclosures</offsets></title><p><offsets xml_i="7683" xml_f="7684" txt_i="2341" txt_f="2342">
</offsets><bold><offsets xml_i="7690" xml_f="7702" txt_i="2342" txt_f="2354">All authors:</offsets></bold><offsets xml_i="7709" xml_f="7734" txt_i="2354" txt_f="2379"> No reported disclosures.</offsets></p></sec></abstract><counts><page-count count="1"></page-count></counts></article-meta></front></article>